

April 27, 2005

Teikoku Hormone Mfg. Co., Ltd.

**Termination of License Agreement on Anticancer Agent TZT-1027
with Daiichi Pharmaceutical**

This is to inform that Teikoku Hormone (President: Takashi Yamaguchi) and Daiichi Pharmaceutical (President: Kiyoshi Morita) have agreed on the termination of the license agreement on an anticancer agent TZT-1027, which had been concluded in December 2000.

Teikoku accepts Daiichi's proposal to terminate the agreement due to Daiichi's strategy that they will concentrate their R&D resources on other projects, and suspends the development of TZT-1027 in Japan. However, Teikoku will seek for new partners and try to continue the development of this product further.